Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis

Abstract

Highlights • Tofacitinib improved ASAS response in ankylosing spondylitis patients.• It ameliorated disease activity, physical function, and quality of life.• 5 mg dose and 16-week treatment showed most favorable efficacy trends.• Safety similar to placebo except for higher risk of upper respiratory infection.